Y-Biologics, Inc. (KOSDAQ:338840)
South Korea
· Delayed Price · Currency is KRW 23,700
-750 (-3.07%)
At close: Apr 27, 2026
Y-Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,913 | 5,763 | 3,479 | 4,151 | 4,847 | Upgrade
|
| Other Revenue | - | - | - | -0 | - | Upgrade
|
| Revenue | 2,913 | 5,763 | 3,479 | 4,151 | 4,847 | Upgrade
|
| Revenue Growth (YoY) | -49.45% | 65.64% | -16.18% | -14.37% | -27.99% | Upgrade
|
| Cost of Revenue | 618.98 | 1,495 | 1,141 | 2,895 | 2,528 | Upgrade
|
| Gross Profit | 2,294 | 4,267 | 2,338 | 1,255 | 2,319 | Upgrade
|
| Selling, General & Admin | 3,999 | 4,704 | 4,974 | 5,130 | 5,143 | Upgrade
|
| Research & Development | 6,783 | 6,828 | 6,650 | 11,941 | 12,589 | Upgrade
|
| Amortization of Goodwill & Intangibles | 122.27 | 123.04 | 119.24 | 117.1 | 97.17 | Upgrade
|
| Other Operating Expenses | 120.16 | 188.11 | 147.22 | 226.04 | 106.36 | Upgrade
|
| Operating Expenses | 11,563 | 12,714 | 12,481 | 20,086 | 19,684 | Upgrade
|
| Operating Income | -9,269 | -8,447 | -10,143 | -18,830 | -17,365 | Upgrade
|
| Interest Expense | -1,259 | -42.93 | -143.76 | -103.44 | -114.73 | Upgrade
|
| Interest & Investment Income | 546.53 | 496.33 | 68.72 | 66.8 | 115.42 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.42 | 38.46 | -55.89 | 96.53 | 309.83 | Upgrade
|
| Other Non Operating Income (Expenses) | -31,992 | 1,513 | -10,922 | 138.54 | -32.11 | Upgrade
|
| EBT Excluding Unusual Items | -41,971 | -6,442 | -21,196 | -18,632 | -17,086 | Upgrade
|
| Gain (Loss) on Sale of Investments | -20.7 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -32.55 | -0 | 324.62 | -172.61 | 15.23 | Upgrade
|
| Pretax Income | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 | Upgrade
|
| Net Income | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 | Upgrade
|
| Net Income to Common | -42,025 | -6,442 | -20,871 | -18,804 | -17,071 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 13 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 13 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 0.79% | 18.02% | 1.85% | 1.01% | 21.93% | Upgrade
|
| EPS (Basic) | -2822.00 | -436.00 | -1667.24 | -1530.00 | -1403.00 | Upgrade
|
| EPS (Diluted) | -2822.00 | -436.00 | -1667.24 | -1530.00 | -1403.00 | Upgrade
|
| Free Cash Flow | -6,865 | -7,003 | -7,801 | -11,193 | -16,720 | Upgrade
|
| Free Cash Flow Per Share | -460.98 | -473.97 | -623.13 | -910.72 | -1374.20 | Upgrade
|
| Gross Margin | 78.75% | 74.05% | 67.21% | 30.25% | 47.85% | Upgrade
|
| Operating Margin | -318.20% | -146.58% | -291.53% | -453.68% | -358.23% | Upgrade
|
| Profit Margin | -1442.67% | -111.78% | -599.90% | -453.06% | -352.17% | Upgrade
|
| Free Cash Flow Margin | -235.66% | -121.52% | -224.21% | -269.68% | -344.94% | Upgrade
|
| EBITDA | -7,337 | -6,409 | -7,788 | -15,869 | -15,049 | Upgrade
|
| EBITDA Margin | -251.87% | -111.21% | -223.86% | - | - | Upgrade
|
| D&A For EBITDA | 1,932 | 2,038 | 2,354 | 2,962 | 2,316 | Upgrade
|
| EBIT | -9,269 | -8,447 | -10,143 | -18,830 | -17,365 | Upgrade
|
| EBIT Margin | - | -146.58% | -291.53% | - | - | Upgrade
|
| Advertising Expenses | 57.54 | 71.25 | 55.98 | 51.34 | 101.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.